These codes are used to report injectable drugs that ordinarily cannot be self-administered; chemotherapy, immunosuppressive drugs and inhalation solutions as well as some orally administered drugs.

View All HCPCS Sections

• J2151

  Injection, mannitol, 250 mg

• J2170

  Injection, mecasermin, 1 mg

• J2175

  Injection, meperidine hydrochloride, per 100 mg

• J2180

  Injection, meperidine and promethazine hcl, up to 50 mg

• J2182

  Injection, mepolizumab, 1 mg

• J2183

  Injection, meropenem (wg critical care), not therapeutically equivalent to j2185, 100 mg

• J2184

  Injection, meropenem (b. braun), not therapeutically equivalent to j2185, 100 mg

• J2185

  Injection, meropenem, 100 mg

• J2186

  Injection, meropenem and vaborbactam, 10mg/10mg (20mg)

• J2210

  Injection, methylergonovine maleate, up to 0.2 mg

• J2212

  Injection, methylnaltrexone, 0.1 mg

• J2246

  Injection, micafungin in sodium (baxter), not therapeutically equivalent to j2248, 1 mg

• J2247

  Injection, micafungin sodium (par pharm) not thereapeutically equivalent to j2248, 1 mg

• J2248

  Injection, micafungin sodium, 1 mg

• J2249

  Injection, remimazolam, 1 mg

• J2250

  Injection, midazolam hydrochloride, per 1 mg

• J2251

  Injection, midazolam in 0.9% sodium chloride, intravenous, not therapeutically equivalent to j2250, 1 mg

• J2252

  Injection, midazolam in 0.8% sodium chloride, intravenous, not therapeutically equivalent to j2250, 1 mg

• J2253

  Injection, midazolam (seizalam), 1 mg

• J2260

  Injection, milrinone lactate, 5 mg

• J2265

  Injection, minocycline hydrochloride, 1 mg

• J2267

  Injection, mirikizumab-mrkz, 1 mg

• J2270

  Injection, morphine sulfate, up to 10 mg

• J2271

  Injection, morphine sulfate, 100mg

• J2272

  Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg

• J2274

  Injection, morphine sulfate, preservative-free for epidural or intrathecal use, 10 mg

• J2275

  Injection, morphine sulfate (preservative-free sterile solution), per 10 mg

• J2277

  Injection, motixafortide, 0.25 mg

• J2278

  Injection, ziconotide, 1 microgram

• J2280

  Injection, moxifloxacin, 100 mg

• J2281

  Injection, moxifloxacin (fresenius kabi), not therapeutically equivalent to j2280, 100 mg

• J2290

  Injection, nafcillin sodium, 20 mg

• J2291

  Injection, nafcillin sodium (baxter), 20 mg

• J2300

  Injection, nalbuphine hydrochloride, per 10 mg

• J2305

  Injection, nitroglycerin, 5 mg

• J2310

  Injection, naloxone hydrochloride, per 1 mg

• J2311

  Injection, naloxone hydrochloride (zimhi), 1 mg

• J2312

  Injection, naloxone hydrochloride, not otherwise specified, 0.01 mg

• J2313

  Injection, naloxone hydrochloride (zimhi), 0.01 mg

• J2315

  Injection, naltrexone, depot form, 1 mg

• J2320

  Injection, nandrolone decanoate, up to 50 mg

• J2323

  Injection, natalizumab, 1 mg

• J2325

  Injection, nesiritide, 0.1 mg

• J2326

  Injection, nusinersen, 0.1 mg

• J2327

  Injection, risankizumab-rzaa, intravenous, 1 mg

• J2329

  Injection, ublituximab-xiiy, 1mg

• J2350

  Injection, ocrelizumab, 1 mg

• J2351

  Injection, ocrelizumab, 1 mg and hyaluronidase-ocsq

• J2353

  Injection, octreotide, depot form for intramuscular injection, 1 mg

• J2354

  Injection, octreotide, non-depot form for subcutaneous or intravenous injection, 25 mcg

---

HCPCS Level II codes and descriptors are approved and maintained jointly by the alpha-numeric editorial panel (consisting of CMS, the Health Insurance Association of America, and the Blue Cross and Blue Shield Association). — Updated 6/4/2026

CPT^® is a registered trademark of the American Medical Association (AMA). All rights reserved.